Tag: Pharmaceutical industry

Cristina Brennan is facing a race against time. By the end of this year, her 12-year-old son Tristan will no longer have access to a crucial medicine that has been instrumental in managing his...

Robert F. Kennedy Jr., former President Trump’s nominee for the position of Health and Human Services Secretary, made his stance clear during his Senate Finance Committee confirmation hearing in Washington. The discussion revolved around...

Key Cancer Drug by AstraZeneca and Daiichi Sankyo Receives First U.S. ApprovalIn a groundbreaking development in the fight against breast cancer, a cutting-edge chemotherapy treatment developed by AstraZeneca and Daiichi Sankyo has been granted...

**Optimizing Online Marketing Strategies for GLP-1 Compounded Drugs: Balancing Benefits and Risks**In Connecticut, the landscape of healthcare is undergoing a transformation as Medicaid tightens its grip on covering GLP-1 medications for obesity, leaving patients...

Lower-Priced Vials of Zepbound Drug Offer Hope for Patient AccessIn a groundbreaking move last year, Eli Lilly introduced lower-priced vials of its popular obesity drug, Zepbound, providing a glimmer of hope for patients struggling...

Lawmakers Urge FTC to Release Report on Pharmacy Benefit Managers A bipartisan, bicameral group of lawmakers has issued a call to the U.S. Federal Trade Commission (FTC) to release an interim staff report on pharmacy...

Eli Lilly Joins Lawsuit on Compounded DrugsIn a recent legal development, pharmaceutical giant Eli Lilly has made a significant move by seeking to join a lawsuit on compounded drugs. This decision comes after a...

Lilly CEO’s Big Payday and Olympics TreatIn the world of biotech, where science and politics intersect, there are always intriguing developments that capture the attention of industry insiders and the general public alike. Today,...

Novo Nordisk, a pharmaceutical giant, recently experienced a setback that sent shockwaves through the industry. The company's highly anticipated next-generation obesity drug, CagriSema, failed to meet investors' expectations, resulting in a significant drop in...